rostafuroxin
Small molecule
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
Latest reported trial: NCT03217825 · Phase 2 · mixed result · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03217825 NCT03217825 · Resistant Hypertension with Adducin/Ouabain Polymorphisms PEARL-HT was a randomized, triple-masked, proof-of-concept trial in never-treated patients with primary hypertension in Italy and Taiwan. Patients were stratified by country and genetic background and randomized to one of three rostafuroxin doses or losartan 50 mg. The primary endpoint was the difference in the fall in office systolic blood pressure after 2 months, assessed in a prespecified pharmacogenomic profile. In Caucasian carriers of that profile, rostafuroxin 50 µg lowered systolic pressure by 9.8 mmHg more than losartan (95% CI 0.6 to 19.0, P = 0.038), but the 500 µg dose did not differ from losartan, and Chinese patients showed no blood pressure change with rostafuroxin. The result is positive only in one genetically defined subgroup at one dose, so it is classed as mixed. The figures come from the peer-reviewed paper (Citterio et al., Pharmacogenomics J 2021). Registry: NCT03217825 | 2 | Systolic Blood Pressure (Week 9 of treatment versus baseline) 2018-02-08 | Fall in office systolic BP after 2 months, rostafuroxin vs losartan 50 mg, in the prespecified genetic-profile population (Caucasian P2a carriers): 50 µg greater fall by 9.8 mmHg (95% CI 0.6 to 19.0), P = 0.038; 500 µg not significant (P = 0.342). Chinese patients: no change in office systolic BP with rostafuroxin. | not yet graded | link ↗ |
View 2 more trials
NCT01320397 NCT01320397 · Resistant Hypertension with Adducin/Ouabain Polymorphisms Registry: NCT01320397 | 2 | Systolic Blood Pressure (Week 9 of treatment versus baseline) 2012-07 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT00415038 NCT00415038 · Resistant Hypertension with Adducin/Ouabain Polymorphisms Registry: NCT00415038 | 2 | Office Systolic Blood Pressure after 5 week of treatment (5 weeks) 2007-04 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.